Development of Synthetic Antigens

 

In the 1950s, Prof. Ephraim Katzir developed simple synthetic models, known as polyamino acids, that made it easier to study the properties of proteins.

 

 

The study of the properties of polyamino acids, and above all of their immunological properties, enabled the development of synthetic antigens, which, among other things, led Weizmann scientists to develop the drug Copaxone, now used worldwide to treat multiple sclerosis.